Q1 2016 13F Holders as of 31 Mar 2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
90
-
Total 13F shares, excl. options
-
21.1M
-
Shares change
-
+4.48M
-
Total reported value, excl. options
-
$191M
-
Value change
-
+$34.3M
-
Put/Call ratio
-
0.7
-
Number of buys
-
60
-
Number of sells
-
-34
-
Price
-
$9.01
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q1 2016
109 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q1 2016.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 90 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.1M shares
of 236M outstanding shares and own 8.94% of the company stock.
Largest 10 shareholders include EAGLE ASSET MANAGEMENT INC (3.82M shares), FMR LLC (1.99M shares), FIRST MANHATTAN CO (1.87M shares), Visium Asset Management, LP (1.41M shares), Nantahala Capital Management, LLC (1.35M shares), BlackRock Fund Advisors (1.3M shares), BANK OF AMERICA CORP /DE/ (1.09M shares), VANGUARD GROUP INC (1.02M shares), PERCEPTIVE ADVISORS LLC (865K shares), and BlackRock Institutional Trust Company, N.A. (770K shares).
This table shows the top 90 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.